Clinical trials: Prostatic Adenocarcinoma
Prostate Cancer, Prostate Adenocarcinoma
Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer
The goal of this clinical trial is to assess the non-inferiority irradiating low and intermediate risk, localized prostate cancer in two fractions of radiotherapy, compared to five fractions of radiotherapy which is the standard…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
- Trial name
- TURBO (NCT06518226)
- Testing
- Ultrahypofractionated MRgRT in 2 fractions, Standard of care: MRgRT in 5 fractions
- Where
- Netherlands
- Volunteers
- 160 people
- Sponsor
- UMC Utrecht
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Anemia, Cardiovascular Complications
Prostate Adenocarcinoma TransCutaneous Hormones
RATIONALE: The increasingly prolonged and extended use of androgen deprivation therapy (ADT) in the treatment of prostate cancer, usually achieved through the administration of LHRH agonists, has raised concerns about long-term…
- Conditions
- Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis
- Trial name
- PATCH (NCT00303784)
- Testing
- Goserelin, Estradiol
- Where
- 32 sites in United Kingdom
- Volunteers
- 2,200 people
- Sponsor
- University College, London
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
ER+ Breast Cancer, Ovarian Cancer
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
This Phase 1b is a dose escalation, MTD expansion and cohort expansions study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.
- Conditions
- ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT03983954
- Testing
- Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab
- Where
- 9 sites in India, Israel
- Volunteers
- 120 people
- Sponsor
- NeoTX Therapeutics Ltd.
Prostate Cancer
Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00081172
- Testing
- lutetium Lu 177 monoclonal antibody J591
- Where
- 3 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
Efficacy and Safety Assessment of IRE of Localized Prostate Cancer.
The purpose of this study is to evaluate safety and short-term oncological efficacy of the NanoKnife Irreversible Electroporation System for localised prostate cancer.
- Trial name
- NCT03504995
- Testing
- Focal irreversible electroporation of the prostate cancer
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Bile Duct Cancer, Gall Bladder Cancer
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous…
- Conditions
- Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors
- Trial name
- NCT05000294
- Testing
- Atezolizumab, Tivozanib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Florida
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
Prostate Cancer
Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer
RATIONALE: Selenomethionine may slow the growth of prostate cancer. Giving selenomethionine before surgery or internal radiation therapy may be an effective treatment for prostate cancer.
- Trial name
- NCT00736164
- Testing
- selenomethionine
- Sponsor
- Roswell Park Cancer Institute
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Prostate Cancer, Pain
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
Azacitidine can reverse clinical resistance to docetaxel through upregulation of Growth Arrest and DNA Damage inducible alpha (GADD45α) and other epigenetically regulated genes.
- Trial name
- NCT00503984
- Testing
- Azacitidine, Docetaxel, Prednisone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
Prostate Cancer, Prostate Adenocarcinoma
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of whole Green Tea Catechin, (Sunphenon® 90D)…
- Trial name
- NCT04300855
- Testing
- Sunphenon
- Where
- 2 sites in United States
- Volunteers
- 115 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
RATIONALE: Imaging procedures such as MRI may improve the ability to determine the response of prostate tumors to therapy. PURPOSE: Phase II trial to study MRI results in patients with prostate cancer that has been treated with…
- Trial name
- NCT00002889
- Testing
- flutamide, goserelin, leuprolide acetate
- Where
- 12 sites in United States
- Volunteers
- 180 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499291
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis
- Sponsor
- Eastern Cooperative Oncology Group
Prostate Cancer
White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy
RATIONALE: White button mushroom extract may stop or delay the development of recurrent prostate cancer. PURPOSE: This phase I trial is studying the side effects and best dose of white button mushroom extract in treating patients…
- Trial name
- NCT00779168
- Testing
- white button mushroom extract, flow cytometry, immunologic technique
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer, Prostate Adenocarcinoma
Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223
This is a prospective biomarker study on prostate cancer patients receiving Radium 223 as standard of care. Participants will take part in this research study because they have chosen Radium 223 treatment for their prostate…
- Trial name
- NCT02981797
- Testing
- Blood Collection During Standard of Care Treatment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00967863
- Testing
- 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Where
- 25 sites in France
- Volunteers
- 500 people
- Sponsor
- UNICANCER
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
This phase II trials studies the side effects and how well ESK981 works in treating patients with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression
- Trial name
- NCT03456804
- Testing
- ESK981
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.